Certara, Inc. filings document the public-company record for a Nasdaq-listed provider of biosimulation software and model-informed drug development services. Its 8-K reports include operating and financial results, guidance-related exhibits, material-event disclosures, credit agreement amendments and the completed sale of its global medical writing and related regulatory services business.
Proxy and governance filings describe annual-meeting matters, board composition, executive transitions and stockholder voting procedures. The record also identifies Certara's common stock, capital-structure disclosures and clinical or regulatory disclosures tied to software, services, regulatory science and clinical-development support.
Certara, Inc. (CERT) reported third-quarter revenue of $94.901 million, versus $90.887 million a year earlier. Net income attributable to common stockholders was $5.592 million, including $9.171 million from discontinued operations; continuing operations recorded a $3.579 million loss, narrower than the $4.838 million loss a year earlier. For the first nine months, revenue was $282.264 million versus $275.342 million, while the continuing-operations loss was $21.485 million versus $1.837 million and net loss attributable to common stockholders was $58.441 million.
For the first nine months, net cash provided by operating activities was $52.412 million versus $67.508 million. Certara completed the sale of its Regulatory and Medical Writing business to Veristat, LLC on May 8, 2026. As of September 30, 2026, Certara had received $78.236 million in cash consideration; $7.5 million remained in escrow for release upon satisfaction of certain post-closing conditions, and Certara is eligible for an earn-out of up to $35 million based on the business’s financial performance following closing. The sale produced an estimated nine-month pretax loss of $56.732 million. Certara also repurchased 9,009,459 shares during the nine-month period, with a $57.389 million cash outflow under its repurchase program.
Certara, Inc. reported third-quarter 2026 continuing-operations revenue of $94.9 million, up 4% year over year. Software revenue rose 11% to $48.8 million, while services revenue fell 2% to $46.1 million. Net loss from continuing operations narrowed to $3.6 million from $4.8 million, and adjusted EBITDA rose 6% to $30.2 million; adjusted EBITDA margin was 31.8%, versus 31.5% a year earlier.
During the first nine months of 2026, continuing-operations net loss was $21.5 million versus $1.8 million in 2025, and cash provided by operating activities from continuing operations was $46.3 million versus $51.4 million. Cash and cash equivalents were $214.9 million at September 30, 2026. Certara narrowed full-year 2026 revenue-growth guidance to 2% to 3% and updated adjusted diluted earnings per share guidance to $0.31 to $0.34. It expects software revenue growth above that range and services revenue growth at or below its low end; a 29% to 31% adjusted EBITDA margin range remains appropriate for the fourth quarter.
Grant Peterson was appointed Chief Product Officer effective November 2, 2026.
Certara, Inc. (CERT) has a notice of proposed sale under Rule 144 filed for the account of officer Leif Pedersen. The filing covers the potential sale of 36,066 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $300,069.12 on NASDAQ.
The shares relate to restricted stock vesting received from the issuer as compensation on April 1, 2026. Certara reports 152,538,780 shares outstanding as of September 3, 2026; this is a baseline figure, not the amount being sold.
Certara, Inc. (symbol: CERT) is the issuer of record for a Form 4 filing submitted to the SEC. Mohammed Faiz reported acquisition or exercise transactions in this Form 4 filing.
Certara, Inc. (CERT) reported that its Interim CFO Mohammed Faiz received a grant of 63,532 Restricted Stock Units on September 1, 2026 under the Certara 2020 Incentive Plan. Each RSU represents a contingent right to one share of common stock or cash. The RSUs vest 50% on July 15, 2027 and 50% on July 15, 2028, subject to continued service, and Faiz now directly holds 63,532 RSUs.
Certara, Inc. clarified financial information related to its recently divested Regulatory and Medical Writing business that had been discussed on its second quarter 2026 earnings conference call and in the accompanying presentation. Management had described the business as having generated approximately $17 million of adjusted EBITDA in 2025 “excluding unallocated overhead costs,” which was incorrect.
The company states that the approximately $17 million of adjusted EBITDA for 2025 is calculated including unallocated overhead costs. On an alternative basis that excludes unallocated corporate expense that will remain with Certara, the business generated approximately $23 million of adjusted EBITDA in 2025. Certara indicates that this clarification does not affect any previously reported financial results, year-over-year comparisons, or its 2026 financial outlook.
Certara, Inc. reported Q2 2026 revenue of $93,271, up from $92,356 a year earlier, but continuing operations shifted to a loss of $6,081 from income of $1,496 as higher operating expenses and interest exceeded revenue.
The company completed the sale of its Regulatory and Medical Writing business to Veristat, receiving $69,435 in cash, with $15,000 in escrow and an earn-out of up to $35,000. The transaction generated a pre-tax disposal loss of $65,481 and contributed to a Q2 net loss attributable to common stockholders of $55,270, or $0.36 per share, versus a $1,968 loss in 2025.
Cash and cash equivalents were $184,138 at June 30, 2026, against term loans of $294,028 and total liabilities of $433,283. Operating activities provided $21,732 in cash in the first half, while the divestiture drove $54,960 of net investing inflows. The company used $57,389 under its repurchase program in the first six months, and as of August 1, 2026, there were 152,538,780 common shares outstanding.
Certara, Inc. reported second quarter 2026 results from continuing operations with revenue of $93.3 million, up 1% from $92.4 million a year earlier. Software revenue grew 4% to $48.8 million, while services revenue declined 3% to $44.5 million. Total bookings were $98.3 million, slightly above $97.4 million in the prior-year quarter.
The company recorded a net loss from continuing operations of $6.1 million versus net income of $1.5 million a year ago, mainly due to higher operating expenses including contingent consideration, currency impacts, and reorganization costs. Adjusted EBITDA was $26.2 million and adjusted net income was $12.5 million, both modestly lower than last year, with adjusted diluted EPS steady at $0.08. Including discontinued operations related to the divested Regulatory and Medical Writing business, total net loss was $55.3 million, or $(0.36) per diluted share.
In May, Certara closed the divestiture of its Regulatory and Medical Writing business and reorganized around two units, Model Informed Discovery and Drug Development and Accelerated Clinical Evidence. A reduction in force affecting about 5% of employees and other actions are expected to deliver approximately $13 million of run-rate savings. The company repurchased $17.4 million of stock in the quarter, completing a $100 million program, and the board authorized an additional $50 million for repurchases. Certara reaffirmed 2026 continuing-operations revenue guidance of $367–$382 million (0–4% growth), with expected adjusted EBITDA margin of 29–31% and adjusted diluted EPS of $0.31–$0.36. Cash and cash equivalents were $184.1 million as of June 30, 2026.
Certara, Inc. announced on August 4, 2026 that Leif E. Pedersen would depart his role as President and Chief Commercial Officer, effective August 1, 2026. He will remain an employee in a Senior Advisor role assisting with transition matters through December 31, 2026.
After December 31, 2026, Mr. Pedersen’s employment will be terminated without cause, and he will be entitled to severance benefits under his existing employment agreement dated July 30, 2020 and the company’s Executive Officer Severance Policy, as described in the “Executive Compensation-Termination and Severance” section of Certara’s Definitive Proxy Statement filed April 3, 2026.
Mohammed Faiz, Interim CFO of Certara, Inc., filed an initial ownership report showing 163686 shares of Common Stock held directly. He also holds equity awards including 8544 Performance Stock Units and Restricted Stock Units covering 13290 and 6330 underlying shares, which vest over time and, for PSUs, depend on total shareholder return through March 31, 2028.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting beneficial ownership of 6,022,686 shares of Certara Inc common stock, representing 3.9% of the class as of June 30, 2026.
Dimensional has sole voting power over 5,913,513 shares and sole dispositive power over 6,022,686 shares, with no shared voting or dispositive power. The shares are held by various funds and accounts for which Dimensional or its subsidiaries acts as adviser or manager. Dimensional may be deemed a beneficial owner but disclaims beneficial ownership, and states that no individual fund’s interest exceeds 5% of the class.